Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - bordetella bronchiseptica (live), strain b-c2 - unknown - bordetella bronchiseptica (live), strain b-c2 active 0.0 - active constituent

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - bordetella bronshiseptica - unknown - bordetella bronshiseptica active 0.0 - active constituent

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - bordetella bronchiseptica fimbriae - unknown - bordetella bronchiseptica fimbriae vaccine active 0.0 - active constituent

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aj vaccines a.s. - diphtheria toxoid (dt) >= 2 iu; tetanus toxoid >= 20 iu; pertussis toxoid (pt) 20 µg - suspension for injection - 0,5 ml - bordetella pertussis; diphteria antigen, adsorbed; tetanus toxoid adsorbed - pertussis, purified antigen, combinations with toxoids

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - bordetella bronchiseptica; canine parainfluenza virus - misc. vaccines or anti sera - bordetella bronchiseptica vaccine-microbial active 0.0 undefined; canine parainfluenza virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 4 weeks old | puppy - kennel cough | infectious tracheobronchitis

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - aluminium hydroxide; bordetella bronchiseptica (inactivated cell free extract; canine parainfluenza virus - inactivated - misc. vaccines or anti sera - aluminium hydroxide mineral-aluminium-base active 3.0 mg/do; bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.05 ug/do; canine parainfluenza virus - inactivated vaccine-viral active 0.0 undefined - immunotherapy - dog - with exclusions see label - bordetella bronchiseptica | canine parainfluenza | canine cough syndrome | infectious tracheobronchitis

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - thiomersal; bordetella bronchiseptica (inactivated cell free extract - parenteral liquid/solution/suspension - thiomersal mercury active 0.1 mg/ml; bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.0 u - immunotherapy - dog | bitch | castrate | puppy - bordetella spp. | bordetella bronchiseptica

Filippini - Ingliż - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - bordetella bronchiseptica vaccine (vet.) - suspension for injection - each ml contains: bordetella bronchiseptica (78-9159 strain) ..... cfu-colony forming unit >3 x 10 cfu

Stati Uniti - Ingliż - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) - unii:qsn5xo8zsu), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (formaldehyde inactivated) (unii: i05o535nv6) (bordetella pertussis pertactin antigen (formaldehyde inactivated) - unii:i05o535nv6) - clostridium tetani toxoid antigen (formaldehyde inactivated) 10 [iu] in 0.5 ml - infanrix is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of infanrix is a contraindication [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including infanrix. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including infanrix. pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized. safety and effectiveness of infanrix in infants aged younger than 6 weeks and children aged 7 to 16 years have not been established. infanrix is not approved for use in these age groups.

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig